Adrea R. Benkoff, M.D.
Relative Benefit to Mother
Side Effects in Pregnant Patients
Potential Risk to Fetus
Structural or Visceral Abnormalities
Altered Physiologic Function of Nursing Baby
An Agent That By Acting During the
Embryonic or Fetal Period Produces
Morphologic or Functional Malformations
That Become Apparent Postnatal
Case Reports
Individual Experience
Animal Studies
Oral Medications
Topical Medications
Absorbed Systemically by Drainage
Through Nasopharyngeal Mucosa
Secreted in Breast Milk
Category A--- Adequate and well controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
Category B--- Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Category C--- Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Category D--- There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Category X--- Studies in animals or humans have demonstrated fetal abnormalities and
/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
TOPICAL ANESTHETICS
No Teratogenic Effects
MYDRIATIC/CYCLOPLEGIC AGENTS
No Animal Studies on Drops
Systemic Use of Atropine, Epinephrine, Homatropine or
Phenylephrine
Minor, Non-Life-Threatening Malformations
Systemic Scopalamine
Fetal Tachycardia and Heart Rate Variability
Systemic Phenylephrine
Fetal Hypoxia and Bradycardia
Unknown if Excreted in Breast Milk
Low Weight Infants are Susceptible to Systemic
Hypertension with 2.5% or 10% Phenylephrine Drops
Avoid Use in Nursing Mothers
All Mydriatic/Cycloglegic Drops – Category C
Relatively Contraindicated Due to Fetal Hypoxia in Late
Pregnancy and Delivery
FLUORESCEIN DYE
Crosses Placenta
Enters Fetus in Humans and Animals
No Adverse Effects Reported in Humans
Category C Rating
Avoid Angiography on Pregnant Patients Especially Those in the First Trimester
Detected in Breast Milk
Stop Breastfeeding for Hours or Days if Used Topically or by
IV
INDOCYANINE GREEN DYE
Used Non-Ophthalmically in Pregnant Women for
Measuring Hepatic Blood Flow
No Adverse Effects on Mother or Fetus
Does Not Cross Placenta
Not Known if Present in Breast Milk
Pregnancy Category C Rating
Use Only if Clearly Indicated
INCIDENCE OF GLAUCOMA
Low in Women of Child-Bearing Age
DISEASE SEVERITY
Young Mothers May Tolerate Small Increases in IOP
During Pregnancy
Decrease or Hold Treatment to Limit Risk to Fetus
Topical Medications Include: Betagan, Betimol, Istalol,
Ocupress, and Timoptic
Systemic Side Effects in General
Respiratory Distress, Bradycardia, Heart Failure, Fatigue,
Depression
Topical Medications Bypass Hepatic Metabolism and Are
Not Inactivated (unlike oral beta-blockers)
Despite Low Dosage
In Children: Bradycardia & Apnea
Systemic Therapy Effects in Pregnancy
Apnea
Intrauterine Growth Retardation
Neonatal Depression at Birth (Low APGAR)
Postnatal Hypoglycemia
Bradycardia
Effects of Topical Use in Pregnancy
Case Reports of Timolol Show Both No Effects and
Adverse Effects
Case Report: Decrease Concentration From 0.5% to
0.25% Decreased Fetal Arrythmia
Beta-Blockers and Breast Feeding
Secreted and Concentrated in Breast Milk
Case Report: Apnea in 18 mo/old Child Being Breast Fed
Rating- Pregnancy Category C
Potential for Serious Adverse Side Effects
Discontinue Nursing or Discontinue Drug, Taking Into
Account the Importance of the Drug to the Mother
Oral Agents (Acetazolamide/Diamox)
Animal Studies: Malformations, Electrolyte Imbalance
National Collaborative Perinatal Project
No Incidence in Major or Minor Fetal Abnormalities in Infants
Where Mothers Took Medication at Different Stages of
Pregnancy
Study Size Considered Too Small
Hepatic and Renal Effects on Infants Being Breast Fed
Topical Agents (Dorzolamide/Trusopt and
Brinzolamide/Azopt)
Published Reports Limited
No Adverse Effects Reported
Not Known if Excreted in Breast Milk
Rating – Pregnancy Category C
Discontinue Nursing or Discontinue Drug, Taking into
Account the Importance of the Drug to the Mother
Epinephrine (Epifrin)
Stimulates Both Alpha and Beta Adrenergic Receptors
Human Studies: Systemic Use in First Trimester
Associated with Minor and Major Anomalies-- Inguinal
Hernias
Rating-- Pregnancy Category C
Dipivefrin Hydrochloride (Propine)
Prodrug of Epinephrine Converted by Corneal Enzymes
Animal Studies: Negative for Side Effects
Not Known if Excreted in Breast Milk
Rating-- Pregnancy Category B
Brimonidine (Alphagan P) —Apraclonidine Hydrochloride (Iopidine)
Selective Alpha-2 Adrenergic Agonists
Case Reports: No Adverse Side Effects During Pregnancy
Not Known if Excreted in Breast Milk
Alphagan P Caused CNS Depression, Somnolence, Apnea in Neonates and
Infants
Rating –
Alphagan P
– Pregnancy Category B
Iopidine
– Pregnancy Category C
Latanaprost (Xalatan), Bimatoprost (Lumigan),
Travoprost (Travatan)
Prostaglandins Action in Labor
Causes Uterine Contractions of Uterine Smooth Muscles
Animal Studies of Systemic Prostaglandins
Increase Risk of Abortion or Preterm Delivery
Human Studies of Topical Prostaglandins
Case Studies: No Adverse Effect on Pregnancy or Neonatal
Outcome
Excretion in Breast Milk
Positive in Animal Studies
Unknown in Humans
Rating —Pregnancy Category C
Because of Potential Effects on Uterine Muscle Contractibility
Prostaglandin Should Be Avoided in Women Who Are Pregnant or Desire to Become Pregnant
Parasympathomimetic Agents
Includes Direct Acting Cholinergic Agents: Pilocarpine &
Carbachol
Animal Studies:
Pilocarpine--Limb Abnormalities
Carbachol – Cervical Vertebrae Abnormalities
Human Study: Systemic Pilocarpine
No Side Effects in First 4 Months of Gestation
Near Term: Neonatal Hyperthermia, Seizures, Restlessness
Rating
—Pregnancy Category C
Systemic Corticosteroids
Increase Risk of Stillbirth
Intrauterine Growth Retardation and Adrenal Insufficiency
Topical Corticosteroids
Animal Studies:
Developmental and Teratogenic Effects Including Cleft Lip,
Cleft Palate & Sex Organ Abnormalities in Mice
Excreted in Breast Milk
Present if Administered Systemically
Suppressed Growth or Interferes with Endogenous
Production
Unknown if Present as a Topical Medication
Rating —Pregnancy Category C
Avoid Use During Nursing Given Potential Serious
Adverse Reactions.
Erythromycin & Polymyxin B
No Known Congenital Defects
Aminoglycosides
Gentamycin, Streptomycin, Tobramycin, Neomycin
Case Studies in Humans: Used IV with No Teratogenic
Abnormalities
Animal Studies: Hearing Loss, Nephrotoxicity
Sulfonamides
Animal Studies: Increase Cleft Palate and Other Bony
Abnormalities
Human Case Reports: Hyperbilirubinemia in Infant if
Used During Third Trimester of Pregnancy
Fluoroquinolones
Animal Studies of Topical Ciloxan, Ocuflox, Quixin,
Vigamox & Zymar:
No Teratogenic Effects
Animal Studies with High Doses
Decrease Body Weights, Delayed Skeletal Development
Tetracycline
Human Case Reports – Systemic Use:
Permanent Discoloration of Teeth in Offspring
Excreted in Breast Milk
Positive with Systemic Erythromycin, Tetracycline &
Ciprofloxacin
Maternal Medications Usually Compatible with Breast
Feeding By American Academy of Pediatrics
Rating:
Pregnancy Category B--Erythromycin
Pregnancy Category C--Gentamycin, Neomycin,
Polymyxin B, Sulfonamides, Fluoroquinolones
Pregnancy Category D-- Tetracycline
Topical: Trifluridine (Viroptic) & Vidarabine ( Vira-A)
For Treatment of HSV Keratitis
Rating – Pregnancy Category C
Avoid in Pregnancy Due to Teratogenic and Tumorgenicity
Effect
Oral: Acyclovir (Zovirax) & Valacyclovir (Valtrex)
For Treatment of Epithelial Corneal Disease
Rating--Pregnancy Category B
Verteporfin (Visudyne)
Human Studies: None
Animal Studies: Increase Anophthalmia and
Microphthalmia in Rat Fetuses
Rating – Pregnancy Category C
Pegaptanib (Macugen)
Human Studies: None
Animal Studies: No Maternal or Fetal Abnormalities
Rating – Pregnancy Category B
Bevacizumab (Avastin)
Human Studies: None
Animal Studies: Teratogenic in Rabbits, Disrupts
Angiogenesis
Rating – Pregnancy Category C
Ranibizumab (Lucentis)
Human Studies: None
Animal Studies : None
Rating-- Pregnancy Category C
Cyclosporine (Restasis)
Immunomodulator
Animal Studies: No Abnormalities
Breast Milk: Excreted When Used Systemically
Rating —Pregnancy Category C
NSAIDS
Flurbiprofen (Ocufen)
Animal Studies: Embryocidal, Prolonged Gestation,
Retarded Growth
Diclofenac (Voltaren)
Animal Studies: Crosses Placenta
Nepafenac (Nevanac)
Animal Studies: Crosses Placenta
Found in Breast Milk
Bromfenac (Xibrom)
Ketorolac (Acular)
All NSAIDS Rating- Pregnancy Category C
Affects Fetal Cardiovascular System
Crosses Placenta
Contains Toxins-- Decrease Oxygen to Fetus
Increases Miscarriage, Low Birth Weight, Premature
Birth, Developmental Delays, Behavioral and Learning
Problems, Increase Childhood Leukemia
Excreted in Breast Milk
Active Ingredient THC-- Impairs Infant Motor
Development
Clear Indication for Use
Relative Benefits vs. Potential Risks
Birth Defects Occur in 2% or More of All Neonates.
Drugs Used Coincidently Might Be Wrongly Implicated as
Contributing to a Birth Defect
Discussion with Patient and Obstetrician
Minimal Effective Dose
Shortest Duration
Limit Systemic Absorption of Drops
Nasolacrimal Duct Occlusion
Eyelid Closure
Removal of Excess Medication with Absorbent Material
Safety Profile Different from Drops
Ointment Creates Reservoir of Active Drug
Prolonged Absorption Time
Reduced Serum Level of Medication
May Create Lower Therapeutic Level Within Eye
Routine Use of Anesthetic Drops or Dilating Drops
Should be Avoided
UNLESS:
New Symptoms Occur
Monitoring of Specific Disease (i.e. Diabetic Retinopathy)
Lowest Concentration and Duration
Tropicamide 0.5%
Fluorescein Dye and ICG Dye
Vitreoretinal Specialists Avoid Use During Pregnancy
Use OCT instead
Corticosteroids
Use Topically with Caution
Antibiotics
Erythromycin —Relatively Safe
Tetracycline —Avoid
Fluoroqinolones —Effects Unknown
Antivirals
Topical Viroptic & Vira-A – Avoid Because of Tumor
Formation and Teratogenic Effect
Oral Zovirax & Valtrex – Relatively Safe For Treatment of
Epithelial Keratitis
Anti-Inflammatory Drugs
Restasis – Use Only if Clearly Needed
NSAIDS – Avoid Use in Late Pregnancy Because of Fetal
Cardiovascular System Complications
Glaucoma Treatment
Prostaglandins
Avoid Due to Effects on Uterine Contractility
Topical Beta Blockers
Reported Positive and Negative for Fetal Side Effects
Topical Carbonic Anhydrase Inhibitors
Relatively Safe After First Trimester
Propine & Alphagan
Both are Pregnancy Category B
Avoid Use of Alphagan at Term of Pregnancy Due to Reports of Apnea and Somnolence in Neonates
Dilating Drops – Avoid Due to Infant Systemic
Hypertension
Fluorescein Dye – If Use Necessary, Must Stop
Breastfeeding for Hours or Days
Corticosteroids – Potentially Serious Side Effects
Antibiotics – American Academy of Pediatrics
Classified Erythromycin, Gentamycin, Tetracycline &
Ciprofloxacin as “Maternal Medications Usually
Compatible with Breast Feeding ”
Antivirals
Topicals – Avoid Unless Benefit Outweighs Risk
Orals – Found in Breast Milk, Use with Caution
Anti-Inflammatory Drugs
Restasis & NSAIDS
– Use with Caution
Glaucoma Treatment
Propine & Alphagan P – Not Known if Excreted in Breast
Milk
Beta Blockers, CA Inhibitors, Pilocarpine, Carbachol,
Epifrin, Iopidine, Prostaglandins – Discontinue Nursing or
Discontinue Drug
Epithelial Lesions
Frequently Dendritic and Often Contain Live Virus
Dendrites May Heal Spontaneously After Debridement and Lubrication
Topical Viroptic Used in Appropriate Dosage Unlikely to
Cause Fetal Damage
Stromal Keratitis
Herpetic Eye Disease Study – Topical Antiviral Therapy with Topical Steroids Reduces Progression and Duration of Disease
Iridocyclitis
Addition of Oral Zovirax to Topical Antiviral Therapy and
Corticosteroid was Beneficial
No Fetal Abnormalities from Oral Zovirax or Valtrex
Reported
Optic Neuritis Treatment Trial
IV Methylprednisolone
Faster Resolution of the Visual Loss but Did NOT Affect
Long-Term Outcome After 6 Months
Decrease Risk of Recurrence of Optic Neuritis and
Development of MS in the Future
No IV Steroids
Only Observation in the First Trimester as the Risk of
Fetal Abnormalities Outweighs the Benefit of Faster
Visual Recovery
Mainstay of Treatment
Topical Cycloplegia
No Teratogenic Effects
Topical Corticosteroids
No Teratogenic Effects
If Oral Steroids and/or Nonsteroidals (Methotrexate)
Are Needed
NO Methotrexate-- Known Teratogen
NO Systemic Steroids – Risk of Cleft Lip and Palate
Consider Periocular or Intravitreal Steroids
Secondary to Reduced Systemic Levels
Weigh Risk/Benefits to Patient
Several Glaucoma Medications Have Potential Adverse Effects in the Fetus or Breastfeeding Infant
Beta-Blockers —Class C
Alpha 2 Agonists (Alphagan P) – Class B
Prostaglandin Analogues – Class C
Topical and Oral Carbonic Anhydrase Inhibitors – Class C
Alternatives Include:
Laser Trabeculoplasty
Observation OFF Treatment
Avoid Glaucoma Surgery
Because of Anesthetic Concerns, Surgical Positioning and Intra and Peri-Operative Medications
Management of Premature Labor and Eclampsia
Beta-Mimetics
Rarely Causes Acute Angle-Closure Glaucoma
Magnesium Sulfate
Ptosis, Accommodative and Convergence Insufficiency with
Diplopia and/or Pupillary Abnormalities
Antiprostaglandins (Indocin)
Decreases IOP Lowering Effect of Epinephrine in Glaucoma
Patients
After Treatment for Premature Labor, Pregnant Woman is Given Glucocorticoids for 2 Days Before Delivery
Glaucoma May Worsen After Steroid Therapy